Study to Compare the Safety and Tolerability of Sativex® in Patients With Cancer Related Pain

PHASE3CompletedINTERVENTIONAL
Enrollment

43

Participants

Timeline

Start Date

April 30, 2002

Primary Completion Date

September 30, 2006

Study Completion Date

September 30, 2006

Conditions
PainCancer
Interventions
DRUG

Sativex

"Containing delta-9-tetrahydrocannabinol (THC), 27 mg/ml: cannabidiol (CBD), 25 mg/ml; both as extract of Cannabis sativa L.~Subjects received study medication delivered in 100 µl actuations by a pump action oromucosal spray. Maximum permitted dose was eight actuations in any three hour period and 48 actuations (THC 130 mg:CBD 120 mg) in 24 hours."

DRUG

GW-2000-02

Containing THC, 27 mg/ml, as extract of Cannabis sativa L. Subjects received study medication delivered in 100 µl actuations by a pump action oromucosal spray. Maximum permitted dose was eight actuations in any three hour period and 48 actuations (THC 130 mg) in 24 hours.

Trial Locations (1)

SY3 8HS

Shropshire and Mid-Wales Hospice, Shrewsbury

Sponsors
All Listed Sponsors
lead

Jazz Pharmaceuticals

INDUSTRY